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Background: It has been suggested that inactivation of p14ARF, a tumor suppressor central to regulating p53
protein stability through interaction with the MDM2 oncoprotein, abrogates p53 activity in human tumors retaining
the wild-type TP53 gene. Differences in expression of tumor suppressor genes are frequently associated with cancer.
We previously reported on a pattern of restricted p53 immunohistochemical overexpression significantly associated
with microsatellite instability (MSI), low TP53 mutation frequency, and MDM2 overexpression in colorectal cancers
(CRCs). In this study, we investigated whether p14ARF alterations could be a mechanism for disabling the p53
pathway in this subgroup of CRCs.
Results: Detailed maps of the alterations in the p14ARF gene were determined in a cohort of 98 CRCs to detect
both nucleotide and copy-number changes. Methylation-specific PCR combined with bisulfite sequencing was used
to evaluate the prevalence and distribution of p14ARF methylation. p14ARF alterations were then correlated with MSI
status, TP53 mutations, and immunohistochemical expression of p53 and MDM2. The frequency of p14ARF mutations
was extremely low (1/98; 1%), whereas coexistence of methylated and unmethylated alleles in both tumors and
normal colon mucosa was common (91/98; 93%). Only seven of ninety-eight tumors (7%) had a distinct pattern of
methylation compared with normal colon mucosa. Evaluation of the prevalence and distribution of p14ARF
promoter methylation in a region containing 27 CpG sites in 35 patients showed a range of methylated CpG sites
in tumors (0 to 25 (95% CI 1 to 13) versus 0 to 17 (95% CI 0 to 2)) in adjacent colon mucosa (P= 0.004).
Hypermethylation of the p14ARF promoter was significantly correlated with the restricted p53 overexpression
pattern (P= 0.03), and MDM2 overexpression (P= 0.02), independently of MSI phenotype. Although no significant
correlation between p14ARF methylation and TP53 mutational status was seen (P= 0.23), methylation involving the
proximal CpG sites within the 5′ CpG flanking exon 1β was present more frequently in tumors with restricted p53
overexpression than in those with diffuse p53 overexpression (range of methylated clones 17 to 36% (95% CI 24 to
36%) versus range 0 to 3% (95% CI 0 to 3%), P= 0. 0003).
Conclusion: p14ARF epigenetic silencing may represent an important deregulating mechanism of the p53-MDM2-
p14ARF pathway in CRCs exhibiting a restricted p53 overexpression pattern.* Correspondence: karin.dahan@uclouvain.be
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The correct functioning of the p53-MDM2-p14ARF path-
way requires a delicate balance between the opposing
effects of its different components [1-3]. Genetic and epi-
genetic alterations have been shown to distort this bal-
ance in various human malignancies, allowing tumor
cells to over-ride the tumor suppressor activity of the
p53 protein, thereby facilitating neoplastic conversion
[4]. In the vast majority of human neoplasia, including
colorectal cancer (CRC), deregulation of the p53 pathway
usually occurs by direct inactivation of the TP53 gene it-
self; this occurs mainly via point mutations [5], which
usually increase the stability of the mutant p53 protein,
leading to its overexpression [6]. However, a significant
proportion of CRCs, which include mainly microsatellite
instability-high (MSI-H) CRCs, and a subset of
microsatellite-stable (MSS) sporadic CRCs, display a par-
ticular immunohistochemical p53 expression pattern
characterized by an accumulation of p53 protein
restricted to a limited number of tumor cells, a profile
that we previously termed ‘restricted p53 overexpression’
[7]. This CRC subgroup has an extremely low frequency
of TP53 mutation, and displays overexpression of MDM2
and normal expression of p21, suggesting that deregula-
tion of p53 pathway in this CRC subgroup may be due to
other alternative mechanisms than TP53 mutation.
Inactivation of the p14ARF gene has been proposed as
a mechanism that is functionally equivalent to an in-
activating p53 mutation, in that it disrupts p53 activity
in tumors retaining the wild-type TP53 gene [4], and
more particularly in sporadic MSI-H CRC [8,9]. In this
study, we examined whether p14ARF inactivation could
be one of the mechanisms disturbing the p53 pathway
in CRCs, particularly in tumors displaying a restricted
p53 overexpression pattern. Therefore, we conductedFigure 1 Methylation of the p14ARF promoter in tumors and normal c
promoter methylation analysis by methylation-specific PCR revealed
products in tumor (T) and adjacent colon mucosa (N). (B) Extensive me
was predominantly detected in tumor, whereas the adjacent colon mucosa
standard molecular weight, control +, positive control for methylated allele
methylase (M.SssI)); H2O, negative control with water only.detailed genetics and epigenetics analysis of the p14ARF
gene in CRC tumors for which we had complete data
on MSI status and DNA mismatch repair deficiency or
sufficiency, and we investigated the relationships be-
tween p14ARF alterations and MSI phenotype, between
p14ARF alterations and the p53 protein expression pat-
tern and its mutational status, as well as with MDM2
protein expression.
Results
p14ARF gene alterations in colorectal cancer
In our sample, we found that p14ARF mutations were ex-
tremely rare; we detected only a previously reported
point mutation in one sample (1/98; 1%). This somatic
missense mutation was detected in exon 2 and corre-
sponds to a C!T transition on a CpG dinucleotide site,
affecting the codon 121 (p.Ala121Val) for the p14ARF
gene, and the codon 107 (p.Arg107Cys) for the p16/
CDKN2A gene. Of the ninety-six patients, five (5%)
patients, including two of the five patients with Lynch
syndrome (hereditary non-polyposis colorectal cancer
(HNPCC); OMIM #120435) were carriers of a poly-
morphic variant corresponding to a substitution of
G!A in codon 148 in exon 2 (p.Ala148Thr) affecting
only the p16/CDKN2A open-reading frame. Gene dosage
detected no copy-number changes in any of the 98 CRCs
examined.
p14ARF promoter methylation in tumors and adjacent
colon mucosa from patients with colorectal cancer
Overall, MSP analysis within the 5′ CpG island of p14/
ARF flanking exon 1β identified coexistence of methy-
lated and unmethylated alleles in tumors and matched
adjacent normal-appearing colon mucosa in 91 of the 98
patients (Figure 1 A). By contrast, a distinct methylationolon mucosa from patients with colorectal cancer (A) p14ARF
coexistence of both unmethylated (U) and methylated (M) PCR
thylation of p14ARF promoter in tumors. The methylated PCR product
produced both the unmethylated and methylated PCR products. MW,
, (bisulfite-modified genomic blood DNA pretreated with the CpG
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the ninety-eight (7.1%) CRCs examined. In these tumors,
MSP results identified only methylated alleles in tumors,
whereas matched adjacent normal colon mucosa con-
tained both methylated and unmethylated PCR products
(Figure 1 B).
Evaluation of density of p14ARF promoter methylation in
tumors and normal colon mucosa from patients with
colorectal cancer
Next, we evaluated the degree of p14ARF promoter
methylation, limiting the analysis to tumors and corre-
sponding adjacent colon mucosa from 35 randomly
selected patients (Table 1), including one of the seven
CRCs that was identified as having heavy methylation by
MSP (sample T2, Table 1).
Using BGS, we analyzed methylation within the 5′
CpG island of p14ARF flanking exon 1β, targeting a re-
gion containing 27 individual CpG sites, including all
the CpG sites analyzed by MSP in this region (see Add-
itional file 1: Figure S1). BGS showed different p14ARF
promoter methylation levels among the 35 tumors and
adjacent colon mucosa tested, with the highest methyla-
tion levels recorded in tumor samples (Figure 2, Figure 3).
Of the 35 tumors examined, the range of fully methylated
CpG was 0 to 25 and the median was 9 (95% CI 1 to 13),
whereas in paired normal colon mucosa the range was 0
to 17 and the median 0 (95% CI 0 to 2) (P=0.004). Of
the thirty-five tumors, eighteen (51%) were extensively
methylated (>9/27 CpG sites methylated, median of fully
methylated CpG sites), six (17%) were partially methy-
lated (>3/27 CpG sites partially methylated, median of
partially methylated CpG sites), and 11 (32%) were
unmethylated (Table 2).
Although the majority of normal colon mucosa tested
(69%) showed a significantly low frequency of methyla-
tion compared with matched tumor samples (P= 0.0019)
(Table 2), extensive methylation was detected in the nor-
mal colon mucosa from six patients, including a patient
with Lynch syndrome (N7; Figure 3) with a germline
mutation in the MLH1 gene (Table 1) and five patients
with sporadic CRC: two MSS tumors (N1, N29; Figure 3)
and three MSI-H tumors (N4, N5, N22; Figure 3) with
activating V600E BRAF somatic mutation associated
with MLH1 epigenetic silencing (Table 1).
Correlation between p14ARF promoter methylation,
clinicopathological features, p53 pathway alterations, and
microsatellite instability status in colorectal cancer
Further, we compared p14ARF methylation data from the
35 randomly selected patients analyzed by BGS with
their clinicopathological features and the molecular
changes in their tumors. No significant association was
seen between p14ARF methylation and either age orgender (Table 2). Although the majority of right-sided
colon tumors (7/10) had increased p14ARF methylation,
no significant association between p14ARF methylation
and tumor location was seen (Table 2). Correlation ana-
lysis identified a significant association between p14ARF
hypermethylation and poorly differentiated or mucinous
tumors (P= 0.0270) (Table 2), but no significant associ-
ation between p14ARF methylation and clinical stage was
seen (Table 2). Compared with tumors exhibiting nega-
tive and diffuse patterns of p53 protein immunohisto-
chemical expression, the tumors displaying a restricted
p53 overexpression profile (15/17) showed a significant
increase in p14ARF methylation (P= 0.0274) (Table 2).
p14ARF methylation was also significantly associated with
MDM2 overexpression (P= 0.0223) (Table 2). Most
tumors exhibiting p14ARF hypermethylation showed an
absence of TP53 mutation (19/24; 79%), but no signifi-
cant association between p14ARF promoter methylation
and TP53 mutational status was seen (Table 2). MSI-H
CRCs were more frequently hypermethylated than MSI-
low (MSI-L)/MSS CRCs (P= 0.0539) (Table 2). However,
after stratification by p53 immunohistochemical expres-
sion pattern, the relationship between MSI status and
p14ARF methylation was no longer significant (Figure 4).
Quantification and distribution of p14ARF promoter
methylation in tumors and normal colon mucosa from
patients with colorectal cancer
We evaluated the density and the distribution of methy-
lation within the 5′ CpG island of the p14ARF promoter
region and exon 1β. Using bisulfite genomic cloning and
direct sequencing, we analyzed 200 clones obtained from
10 tumors and matched adjacent colon mucosa. For
each clone, the methylation status of each individual
CpG site was determined (Figure 5). For all 27 CpG sites
evaluated, we found a significantly (P <0.0001) increased
number of methylated clones in tumors (median 38%;
95% CI 25 to 41%; range 13 to 47%) compared with the
adjacent normal colon mucosa (median 9%; 95% CI 5 to
13%; range 1 to 24%) (Table 3). Although most normal
colon mucosa (7/10) showed only sparse methylation
(Figure 5), densely methylated clones were seen in three
of the ten normal colon mucosa tested (N1, N18 and
N29; Figure 5). Bisulfite genomic cloning and direct se-
quencing also showed that methylation involving both
CpG sites within the proximal and the distal region of
the 5′ UTR CpG island of the p14ARF flanking exon 1β
(nucleotide position −69 to position +4 relative to the
translation codon ATG) is not a frequent event in CRC,
but seems to occur more particularly in tumors display-
ing a restricted pattern of p53 overexpression, including
MSI-H and MSS tumors (Figure 5). Overall, the 3′ re-
gion of exon 1β was more densely methylated (median
41%; 95% CI 38 to 43%; range 27 to 47%) than the
Table 1 Clinicopathological and molecular data for patients analyzed by bisulfite genomic sequencing
Patient’s number Location Type of differentiation Stage MMR IHC MSI status p53 IHC TP53 mutation
1 Sigmoid Moderate IV Positive MSS D p.R248W
3 Sigmoid Moderate IIIB Positive MSS D No
11 Left Moderate IV Positive1 MSI-H D No
12 Rectum Moderate IIA Positive MSS D p.R273C
15 Sigmoid Well IV Positive MSS D p.R248Q
24 Left Moderate IIA Positive MSS D No
26 Rectum Well I Positive MSS D p.R248W
28 Rectum Moderate IV Positive MSS D No
30 Sigmoid Poor IIIB Positive MSS D p.C135R
33 Rectum Well IIA Positive MSS D No
34 Left Well IIB Positive MSS D No
35 Right Well IIA Positive MSS D p.[R158H (+)R267Q]
17 Sigmoid Well I Positive MSS D p.R248Q
2 Right Well IIA MLH1-/PMS2-† MSI-H R No
4 Right Mucinous IIIC MLH1-/PMS2-{ MSI-H R No
5 Left Mucinous IIA MLH1-/PMS2-{ MSI-H R No
6 Right Well IIA MSH2-/MSH6-† MSI-H R No
7 Right Poor IIA MLH-/PMS2-{ MSI-H R No
8 Left Poor IV Positive MSS R No
9 Right Mucinous IIIB Positive MSS R No
10 Right Mucinous IIIB MLH1-/PMS2-† MSI-H R No
13 Left Well IIA Positive MSS R No
14 Left Well IV Positive MSS R No
16 Sigmoid Mucinous IIA Positive MSS R No
18 Rectum Poor IIIC MLH1-/PMS2-{ MSI-H R No
19 Left Well I MLH1-/PMS2-† MSI-H R No
22 Right Mucinous IIIB MLH1-/PMS2-{ MSI-H R No
23 Right Poor IIA MLH1-/PMS2-1 MSI-H R No
25 Left Mucinous IIA Positive MSS R No
29 Left Moderate IIA Positive MSS R No
20 Rectum Moderate IIA Positive MSS N No
21 Rectum Mucinous IIB Positive MSS N p.[K291X(+) H297Y]
27 Rectum Moderate IIA Positive MSS N c.672 + 1 G!A
31 Right Moderate IIIC Positive MSS N p.Q165X
32 Rectum Moderate IIIC Positive MSS N No
Abbreviations: MMR, DNA mismatch repair system; MSI, microsatellite instability; MSI-H, microsatellite instability-high; MSS, microsatellite-stable; IHC,
immunohistochemistry; D, diffuse pattern of p53 expression, R, restricted pattern of p53 expression, N, negative pattern of p53 expression.
*MMR deficiency with unknown origin.
†Lynch syndrome.
{Sporadic MSI-H colorectal cancer with activating V600E BRAF somatic mutation, indicating MLH1 epigenetic silencing.
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CI 17 to 25%; range 13 to 25%) (P= 0.0001) (Table 3).
However, the number of methylated clones on CpG sites
within the proximal region of the 5′ CpG island of
p14ARF was significantly higher in tumors displaying arestricted pattern of p53 overexpression (median 30%;
95% CI 24 to 36%; range 17 to 36%) than in tumors
exhibiting a strong diffuse p53 expression pattern (me-
dian 0%; 95% CI 0 to 3%; range 0 to 3%) (P= 0.0003)
(Table 3).
Figure 3 p14ARF promoter methylation in adjacent colon mucosa.
Figure 2 Heterogeneity of p14ARF promoter methylation in colorectal tumors. The samples analyzed are represented on the horizontal line,
and the 27 CpG sites on the vertical line. For each case, the methylation status of each individual CpG site is shown: an empty block indicates
that the concerned CpG site is unmethylated, a black block indicates that the concerned CpG sites is fully methylated, and a gray block indicates
that the concerned CpG site is partially methylated.
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Table 2 Relationships between p14ARF promoter methylation and clinicopathological data, p53 and MDM2 protein





p14ARF promoter methylation profile
Unmethylated Dense or partial methylation P value
Age, years, mean± SD 64± 12 69 ± 10 0.20571
Gender
Male 16 (46%) 5 (45.5%) 11 (45.8%) 0.9833
Female 19 (54%) 6 (54.5%) 13 (54.2%)
Type of tissue
Tumor 35 11 (31%) 24 (69%) 0.0019
Adjacent colon mucosa 35 24 (69%) 11 (31%)
Tumor location
Right side 10 (29%) 3 (27.3%) 7 (29.2%) >0.05
Left side 25 (71%) 8 (72.7%) 17 (70.8%)
Differentiation
Well or moderate 22 (62.9%) 10 (90.9%) 12 (50%) 0.0270
Poor or mucinous 13 (37.1%) 1 (9.1%) 12 (50%)
Clinical stage
Stage I 3 (8.6%) - 3 (12.5%) 0.46742
Stage II 17 (48.6%) 5 (45.4%) 12 (50%)
Stage III 9 (25.7%) 3 (27.3%) 6 (25%)
Stage IV 6 (17.1%) 3 (27.3%) 3 (12.5%)
p53 immunohistochemistry
Negative pattern 5 (14.3%) 3 (27.3%) 2 (8.3%) 0.02752
Diffuse pattern 13 (37.1%) 6 (54.5%) 7 (29.2%)
Restricted overexpression 17 (48.6%) 2 (18.2%) 15 (62.5%)
MDM2 immunohistochemistry
Negative 12 (34.3%) 7 (63.6%) 5 (20.8%) 0.0223
Overexpression 23 (65.7%) 4 (36.4%) 19 (79.2%)
p21 immunohistochemistry
Loss to mild 9 (25.7%) 6 (54.5) 3 (12.5%) 0.01462
Moderate to high 26 (74.3%) 5 (45.5) 21 (87.5%)
TP53 mutational status
Mutation present 10 (28.6%) 5 (45.5%) 5 (20.8%) 0.2266
No mutation detected 25 (71.4%) 6 (54.5%) 19 (79.2%)
MSI status
MSI-H 11 (31.4%) 1 (9.1%) 10 (41.7%) 0.0539
MSS 24 (68.6%) 10 (90.9%) 14 (58.3%)
Abbreviations: MSI, Microsatellite instability, MSI-H, microsatellite instability-high; MSS, microsatellite-stable.
2Two-sided two-sample t-test.
2Two-tailed Fisher’s exact test.
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The purpose of this study was to investigate whether
alteration of p14ARF, a key regulator of p53-MDM2
interaction, plays a role in deregulating the p53 path-
way in a subgroup of CRCs exhibiting a restricted pat-
tern of p53 overexpression significantly associated with
MSI-H phenotype, low TP53 mutation, and MDM2overexpression, and inversely correlated with p21 ex-
pression loss [7].
Contrary to the usual situation in solid tumor types
such as melanoma, pancreatic tumors and some lung
tumors [10-12], the present study confirmed the ex-
tremely low frequency of intragenic mutations and allelic
losses at the p14ARF locus in CRC [13]. Indeed, direct
Figure 4 Relationship between p14ARF promoter methylation
and microsatellite instability (MSI) status. The MSI-high (MSI-H)
tumors had an overall higher frequency of p14ARF promoter
methylation compared with MSS tumors, but after stratification by
restricted p53 overexpression, the relationship between p14ARF
methylation and MSI status was no longer significant.
Figure 5 Density and distribution of methylated CpG within the 5′ Cp
methylated CpG in tumors (up) and corresponding adjacent colon mucosa
(represented on horizontal line (a) to (j) were examined. The circles on the
individual clone. Note that the translation start site is located between CpG
is unmethylated, a black circle indicates that the concerned CpG site is me
p53 immunohistochemistry are indicated. MSI-H, microsatellite instability-hi
p53 R, restricted pattern of p53 overexpression.
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sense mutation affecting both the p14ARF and p16/
CDKN2A genes [14]. Only 5% percent of the cases, in-
cluding two patients with Lynch syndrome, were carriers
of p.Ala148Thr, a variant considered a non-synonymous
single nucleotide polymorphisms (nsSNP, rs3731249)
[14,15]. Although the functional significance of this SNP
has been controversial in studies of several cancer types
[15-17], its role in CRC risk assessment warrants investi-
gation because this variant occurred at an evolutionarily
conserved amino acid with a low intolerance index, as
predicted by the Sorting Intolerance from Tolerance
(SIFT) program [18].
We evaluated epigenetic changes within the p14ARF
promoter using two different methylation assays, MSP
and BGS. We used MSP because it is widely recognized
as a highly sensitive methylation assay, allowing detec-
tion of up to 0.01% of methylated alleles of a given CpG
island [19]. However, this method provides only qualita-
tive data, so for quantitative analysis, BGS complemen-
ted by cloning and direct sequencing, was used [20-22].G island of p14ARF flanking exon 1β. Depicted is the distribution of
(down) from 10 patients. For each case, 10 independent clones
vertical line represent the 27 CpG (CpG 1 to 27) sites analyzed for each
sites 8 and 9. An empty circle indicates that the concerned CpG site
thylated. For each tumor, the microsatellite instability (MSI) status and
gh; MSS, microsatellite-stable; p53 D, diffuse pattern of p53 expression,





















1 −69 13 5 3 17
2 −43 17 1 0 24
3 −40 22 1 0 31
4 −35 25 4 0 36
5 −28 22 2 0 31
6 −22 19 2 0 27
7 −10 22 5 3 30
8 −7 21 3 0 30
9 +4 30 5 3 41
10 +25 41 8 37 43
11 +31 42 12 43 41
12 +34 45 12 50 43
13 +36 43 18 43 43
14 +38 34 12 33 34
15 +42 43 13 43 43
16 +47 41 15 53 36
17 +50 45 9 50 43
18 +52 43 12 57 37
19 +66 47 9 50 46
20 +80 44 9 50 41
21 +82 40 13 37 41
22 +90 38 13 27 43
23 +105 38 13 47 34
24 +114 41 19 50 37
25 +118 34 17 37 33
26 +121 31 24 37 29
27 +133 27 9 13 33
The percentage of methylated clones was calculated in all tumors (n = 10, ≥10 clones analyzed for each tumor) and adjacent normal colon mucosa (n = 10, ≥ 10
clones analyzed for each sample) for every CpG site. The percentage of methylated clones was higher in tumors median 38%, 95% CI 25-41%; range 13-47%),
than in normal colon mucosa (median 9%, 95% CI 1 to 24; range 1 to 24%) (Wilcoxon rank sum test, P <0.0001). The percentage of methylated clones on proximal
CpG sites was also higher in tumors with a restricted p53 overexpression pattern (median 30%, 95% CI 24 to 36%, range 17 to 36%) than in tumors with a diffuse
p53 overexpression pattern (median 0%, 95% CI 0 to 3%, range 0 to 3%) (Wilcoxon rank sum test, P= 0.0003).
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is less sensitive than MSP as detection requires at least
25% of the alleles to be methylated [22], suggesting a risk
of disagreement between the two methods.
One of our main findings was the detection of p14ARF
promoter silencing as a potential cause of deregulation
of the p53-MDM2-p14ARF signaling axis in a specific
subgroup of CRCs. Using BGS, we fully characterized 35
of the 98 CRCs analyzed. A significant increase in
p14ARF promoter methylation was evident in 24 CRCs
(69%), and interestingly, 63% of the cases (15/24) weretumors exhibiting the restricted pattern of p53 overex-
pression (Figure 2, Table 2).
The p14ARF promoter has been previously reported to
be preferentially hypermethylated in CRCs retaining the
wild-type TP53 gene [8,13,23], and has been particularly
associated with sporadic MSI-H CRCs associated with
MLH1 epigenetic silencing [8,9]. In addition to the rela-
tionship between the restricted p53 overexpression pat-
tern and the MSI-H phenotype [7], we found that
p14ARF promoter methylation was increased in CRCs
with restricted p53 overexpression, irrespective of MSI
Nyiraneza et al. Clinical Epigenetics 2012, 4:9 Page 9 of 13
http://www.clinicalepigeneticsjournal.com/content/4/1/9status (Figure 4). This observation, along with our previ-
ous findings, shows that regardless of the MSI status,
CRCs with the restricted p53 overexpression pattern ex-
hibit a significant overlap in terms of their pathobiology,
supporting the hypothesis of a common tumorigenic
event [7]. In agreement with these observations, previ-
ous studies have shown that although CRCs have been
reported to evolve either through the classic chromo-
somal instability pathway or through the alternative MSI
pathway known to be significantly associated with the
CpG island methylator phenotype, the mechanisms
underlying these genomic instability pathways are not al-
ways independent [24,25], and a significant degree of
overlap can therefore be expected in some tumors, re-
gardless of the MSI status.
Even though a high frequency of p14ARF promoter
methylation has been previously reported to occur in
tumors without TP53 mutations [8,13,23,26], an inverse
correlation between TP53 mutations and epigenetic in-
activation of p14ARF in CRCs does not always hold true
[27]. In the current study, we found that although the
majority of heavily methylated tumors did not have a
TP53 mutation, p14ARF promoter methylation was
increased in almost half of tumors (5/10) carrying TP53
mutations (Table 2). Interestingly, the most exceptional
feature of these tumors was the distribution of p14ARF
methylation. Using bisulfite genomic cloning and direct
sequencing, we found that extensive methylation involv-
ing both the proximal and the distal CpG sites within
the 5′ CpG island of p14ARF flanking exon 1β was rare
in CRC generally, but occurred more frequently in CRCs
displaying a restricted pattern of p53 overexpression
(Table 3). In tumors showing a strong diffuse p53 ex-
pression pattern associated with missense TP53 muta-
tions, the majority of the methylated clones exhibited
partial methylation involving CpG sites downstream
from the translation start site and extending throughout
exon 1β (Figure 5, Table 3). This pattern of methylation
was also seen in some normal colon mucosa (Figure 3;
Figure 5 (N29)). Our results support previous observa-
tions by Zheng et al., who showed that partial methyla-
tion is the most common pattern of p14ARF methylation
in primary sporadic CRCs [28].
Owing to the limited availability of an efficient anti-
body raised against the p14ARF protein, we were unable
to examine p14ARF expression by immunohistochemistry
in our tumor samples. However, previous experiments,
mainly performed in CRC cell lines, have shown that ex-
tensive methylation of CpG sites within the 5′ CpG is-
land and exon 1β of p14ARF is associated with
transcription silencing and correlates with extremely low
levels of p14ARF mRNA, whereas partial methylation
correlates with intermediate mRNA expression [28,29].
Based on these findings, we suggest that the extensivemethylation seen in CRCs with restricted p53 overex-
pression may represent an important functional defect
in the p14ARF gene, but additional studies are needed to
verify this hypothesis.
Additionally, a significant relationship between MDM2
overexpression and increased p14ARF methylation was
seen (79%; P= 0.0223). It is known that tumors with
reduced p14ARF activity have higher MDM2 activity,
which potentially leads to p53 inactivation [30]. More-
over, using immunohistochemistry, a strong inverse rela-
tionship between MDM2 and p14ARF inactivation has
been previously found in different tumor types, includ-
ing a subtype of human lung carcinoma displaying an
abnormally stabilized p53 protein [31]. Therefore, it is
conceivable that the increased MDM2 expression seen
in CRCs with restricted p53 overexpression may reflect
cellular functional consequences of p14ARF epigenetic in-
activation. Interestingly, a previous study found an asso-
ciation between p14ARF epigenetic silencing and an
abnormal cytoplasmic localization of MDM2 in primary
CRC and tumor cell lines, mainly explained as a direct
consequence of p14ARF loss of function [32]. In the
current study, we did not find any MDM2 subcellular
localization in our cohort of 98 CRCs. Functional inter-
pretation of MDM2 immunostaining data are compli-
cated by the existence of several isoforms, of which
detection depends on the antibody used, and this may
explain these discrepancies.
It is widely believed that CpG islands in autosomal
genes are usually unmethylated, except when associated
with certain imprinted genes and with genes that
undergo X-chromosome inactivation in females [33,34].
Supporting this paradigm, initial studies indicated
methylation of the 5′ CpG island of the p14ARF pro-
moter exclusively in tumor cells [13,27]. However, this
view was challenged by detection of p14ARF methylation
in normal colon mucosa from patients with CRC and
from healthy people without clinical evidence of colon
cancer [8,35,36]. In the current study, using the MSP
assay, we found coexistence of unmethylated and methy-
lated alleles in the majority of tumors and in all adjacent
normal colon mucosa. A clear difference in methylation
pattern between tumor and adjacent normal colon mu-
cosa was seen only in the seven tumors (7.1%) that
showed heavy methylation. The sensitivity of our MSP
assay was significantly high. However, given that we used
the conventional MSP assay, which provides qualitative
data, we were limited by this high sensitivity, and were
unable to distinguish the p14ARF methylation occurring
in a small proportion of cells from the high-level methy-
lation associated with epigenetic inactivation. Using the
BGS approach, we found that the level of p14ARF methy-
lation in normal tissues was generally below the thresh-
old detection of the BGS assay, and was significantly
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cosa. However, hypermethylation was still present in
normal colon mucosa from some patients, and more fre-
quently in those with DNA mismatch repair deficiency
associated with MLH1 gene inactivation. Indeed, hyper-
methylation of the 5′ CpG islands of the p14ARF and
MLH1 genes in normal-appearing mucosa surrounding
colorectal neoplastic lesions has been described as a
‘field cancerization’ phenomenon, which may occur be-
fore genetic alterations in the early stages of carcinogen-
esis [37].
Conclusion
In summary, this study provides evidence that p14ARF
promoter hypermethylation may represent an important
cause of deregulation of the p53-MDM2-p14ARF signal-
ing axis in a subgroup of CRCs displaying a restricted
overexpression pattern of the p53 protein, associated
with the wild-type TP53 gene, concomitant MDM2 over-
expression, and normal p21 expression. Although this
subgroup of CRCs includes the majority of MSI-H
tumors (namely Lynch syndrome-related CRCs and
sporadic MSI-H CRCs), methylation involving both
proximal and distal CpG sites within the 5′ CpG island
flanking exon 1β of p14ARF preferentially occurs in these
tumors independently of MSI status. Further investiga-
tions are warranted to clarify the significance of this
high-level methylation on the transcriptional activity of
the p14ARF gene. The results from this work could have
clinical implications, because therapeutic delivery of
small p14ARF peptides has been reported to mimic the
growth-inhibitory effects of full-length p14ARF expres-
sion and to restore p53 activity in cancers in which
MDM2 is overexpressed or p14ARF is functionally inacti-
vated [38]. Evaluation of the clinical relevance of such
promising therapeutic measures would essentially pro-
vide a new set of more efficient treatment possibilities in
patients with CRC who have tumors displaying the
restricted pattern of p53 overexpression.
Methods
Ethics approval
Tissues collection and analyses were approved by the in-
stitutional ethics committee of the Catholic University of
Louvain (Faculty of Medicine UCL), and all participants
provided written informed consent.
Patients
We examined 98 surgical resected tumors and corre-
sponding adjacent normal colon mucosa from the co-
hort of patients (48 men, 50 women, mean ± SD age
64 ± 14 years) with primary CRC we reported previously
[7]. For the 98 CRCs, clinicopathologic data and evalu-
ation of the DNA mismatch repair (MMR) system (usingMSI analysis, immunohistochemistry (IHC) for MMR
proteins, MMR germline mutation) and somatic BRAF
mutation, had been performed previously [7], but only
data from the 35 patients extensively studied by bisulfite
genomic sequencing (BGS) are shown in Table 1. Immu-
nohistochemical analysis for p53, MDM2, and p21 pro-
teins and mutational analysis for TP53 were also
previously performed. Three distinct patterns of p53 ex-
pression were seen, including a restricted p53 overex-
pression pattern clearly distinguishable from both the
negative pattern and the strong diffuse pattern [7].
MDM2 immunohistochemical expression was semi-
quantitatively evaluated based on the percentage of posi-
tive tumor cells. MDM2 overexpression was recorded if
a positive staining was evidenced in more than 10% of
tumor cells nuclei [7].
p14ARF mutation screening and gene dosage
Sequence-specific primers (according to GenBank acces-
sion number NM_058195) for exon 1β and exon 2
(common to both p16/CDKN2A and p14ARF), including
the intronic flanking regions of the p14ARF gene, were
designed using Primer3 software (http://frodo.wi.mit.
edu/cgi-bin/primer3/primer3.cgi). PCR was carried out
for each sample, and PCR products were then purified,
sequenced, and run on an automated laser fluorescent
DNA sequencer (3130XL; AB Applied Biosystems, Fos-
ter City, CA, USA). To detect large rearrangements (al-
lelic imbalances) throughout the p14ARF locus, multiplex
ligation-dependent probe amplification (MLPA) was per-
formed using (Salsa PO24B 9p21 CDKN2A/2B region
kit; MRC-Holland BV, Amsterdam, the Netherlands), in
accordance with the manufacturer’s instructions. MLPA
PCR products were separated by capillary electrophor-
esis using an automated laser fluorescent DNA sequen-
cer (3130 XL; AB Applied Biosystems, Foster City, CA,
USA). The relative quantities of the amplified probes in
each sample were determined using Genotyper (Applied
Biosystems, Foster City, CA, USA) and Excel (Microsoft
Corp., Redmond, WA, USA) software (Gene Marker ver-
sion 1.5; Softgenetics Inc, State College, PA, USA). The
gene dosage quotient was generated using peak height
rather than peak area as an indicator of DNA template
amount [39,40]. For each sample, a gene dosage quotient
score (peak height relative to control) was calculated
and adjusted as follows: homozygous loss ≤ 0 to
0.19 ≤ hemizygous loss ≤ 0.7 to 0.75 ≤wild-type ≤ 1 to
1.3 < duplication.
Methylation-specific PCR
Genomic DNA was extracted from frozen tumors and
matched normal tissues using a standard phenol/chloro-
form method. Thereafter, bisulfite treatment of 300 ng
of genomic DNA was performed (Applied Biosystems
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with the manufacturer’s instructions (Applied Biosys-
tems, Foster City, CA, USA). Methylation-specific PCR
(MSP) [19] was performed to examine p14ARF promoter
methylation within a region located at least −60 base
pairs relative to the translation codon, previously
reported to be associated with p14ARF gene silencing in
CRC [27]. Methylation in this region was evaluated
using the primer sets previously described [27]. These
primers pairs allowed assessment of the methylation sta-
tus of six CpG dinucleotides specific for the 5′ CpG is-
land of the p14ARF gene flanking exon 1β (see Additional
file 2: Table S1). The MSP reactions were carried out in
a total volume of 25 μl containing 2.5 μl of the manufac-
turer’s 10× PCR buffer (Roche Diagnostics, Basel, Switz-
erland), 1.5 μl of 25 mmol/l MgCl2, and 0.25 μl of
100 μmol/l dNTPs (dATPs, dTTPs, dCTPs and dGTPs),
1 μl of primer (10 pmol/μl for each), 1 to 1.25 U of
DNA polymerase (FastStart; Roche Diagnostics, Basel,
Switzerland), and 1 μl of bisulfite-modified genomic
DNA. Normal human leukocyte DNA was methylated
in vitro with a CpG methylase (M.SssI; New England
BioLabs, Beverly, MA, USA) in accordance with the
manufacturer’s instructions, and used as the MSP
methylated-allele positive control. After amplification,
5 μl of PCR products were run in an 8% non-denaturing
acrylamide gel with an appropriate size marker. Ampli-
cons were visualized by ethidium bromide staining
under UV illumination.
Bisulfite genomic sequencing
BGS primers designed to recognize both methylated and
unmethylated alleles were generated based on the
human contig sequence (GenBank accession number
L41934) using MethPrimer software (http://www.uro-
gene.org/methprimer/index1.html) [41]. The designed
BGS primers were located within the 5′ CpG island of
the p14ARF region flanking exon 1β, and were used to
amplify a DNA sequence containing 27 CpG sites, in-
cluding all the CpG sites targeted by the MSP primers
within this region (see Additional file 1: Figure S1).
Bisulfite-converted DNA samples from tumor tissue and
corresponding adjacent normal tissues from 35 patients,
randomly selected from our cohort of patients (Table 1),
were subjected to PCR amplification using primer pair A
and B (forward and reverse, respectively), followed by a
nested PCR amplification with primer pair C and D (for-
ward and reverse; Additional file 1: Figure S1). All the
primer sequences used are summarized in (Additional
file 2: Table S1). After PCR amplification, the BGS pro-
ducts were purified (Qiaquick PCR Purification Kit; Qia-
gen Inc., Valencia, CA, USA), and directly sequenced in
both directions using primers C and D (forward and re-
verse; see Additional file 1: Figure S1) with a commercialkit (Big Dye Terminator Cycle Sequencing Ready Reac-
tion Kit, version 1.3; Perkin Elmer/Applied Biosystems,
Foster City, CA, USA) in accordance with the manufac-
turer’s instructions. Sequencing reaction products were
purified on filter plates for high-throughput separation
(Multiscreen™; Millipore Corp., Bedford, MA, USA)
using dextran gel beads (SephadexTM G-50 Fine Beads;
GE Healthcare Bio-Sciences AB, Uppsala, Sweden) in ac-
cordance with the manufacturer’s instructions. After
purification, sequencing reaction products were run on
an automated laser fluorescent DNA sequencer
(3130XL; AB Applied Biosystems, Foster City, CA,
USA). Results were analyzed using the sequencing ana-
lysis software for the sequencer (Version 1.5; AB Applied
Biosystems, Foster City, CA, USA).
For all 35 patients examined, the bisulfite sequencing
chromatogram was analyzed for each individual CpG
site, and a specific pattern was assigned: 1) unmethylated,
in which the CpG site was fully converted into thymi-
dine, indicating that the concerned CpG site is unmethy-
lated on both alleles (see Additional file 3: Figure S2), 2)
partial, showing an overlap of both thymidine and cyto-
sine peaks on a sequencing chromatogram, indicating
the presence of both methylated and unmethylated
alleles (see Additional file 3: Figure S2 A), 3) methylated,
in which the CpG site was fully methylated, indicating
that the concerned CpG site is extensively methylated on
both alleles (see Additional file 3: Figure S2 B).
Cloning and sequencing
For 10 patients, the amplified bisulfite PCR products
from tumor and corresponding normal colon tissues
were purified (Qiaquick PCR Purification Kit; Qiagen)
and ligated into a pTZ57R/T plasmid vector using a TA
cloning and bacterial transformation system (Ins TAclone™
PCR Cloning Kit). The plasmid was inserted into Escher-
ichia coli cells, which were cultured overnight, then re-
combinant plasmid DNA was isolated and purified
(Rapid Miniprep Plasmid Purification System; Marligen
Bioscience, Ijamsville, Maryland, USA). Purified plasmid
recombinant DNA was subjected to direct PCR amplifi-
cation in a 25 μl reaction mixture containing 2.5 μl of
the manufacturer’s 10× PCR buffer (Roche Diagnostics,
Basel, Switzerland), 1.5 μl of 25 mmol/l MgCl2, and
0.25 μl of 100 μmol/l dNTPs, 1 μl of M13 forward and re-
verse primer (10 pmol/μl for each), 1 U of DNA polymer-
ase (FastStart; Roche Diagnostics, Basel, Switzerland), and
1 μl of purified recombinant plasmid DNA template.
Direct sequencing was performed in both directions
using M13 primers with a commercial kit (Big Dye
Terminator Cycle Sequencing Ready Reaction Kit, ver-
sion 1.3; Perkin Elmer/Applied Biosystems, Foster
City, CA, USA) in accordance with the manufacturer’s
instructions. Sequencing reaction products were purified
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screen™; Millipore Corp., Bedford, MA01730 USA) using
dextran gel beads (SephadexTM G-50 Fine Beads; GE
Healthcare Bio-Sciences AB, Uppsala, Sweden) and were
run on an automated laser fluorescent DNA sequencer
(3130XL; AB Applied Biosystems, Foster City, CA, USA).
For each sample, at least 10 clones were analyzed. For each
clone, the bisulfite genomic sequence was analyzed, and for
each individual CpG site a methylation status was assigned.
Statistical analysis
We used the Pearson χ2 test (when the minimum
expected value was≥ 5) or the two-tailed Fisher’s exact
test (when the minimum expected value was <5) to
compare the frequency of p14ARF promoter methylation
in 35 patients with CRC in relation to various clinico-
pathologic parameters and characteristics, including
immunohistochemical expression of p53, MDM2, and
p21, p53 mutational status and MSI status. Comparison
in distribution and density of methylation between
tumors and adjacent normal-appearing colon mucosa,
and of tumor groups were assessed using the Mann–
Whitney or Wilcoxon rank sum test. All statistical ana-
lyses were performed using the NCSS 2007 statistical &
Power analysis software. All reported P-values were two
sided, and the test was significant when the P ≤ 0.05.
Additional files
Additional file 1: Figure S1 p14ARF promoter methylation analysis
by bisulfite genomic sequencing (BGS). The genomic sequence of 5′
CpG island of p14ARF region flanking exon 1β was analyzed. The
highlighted and numbered CpG indicates the 27 potential CpG sites
analyzed. Bold arrows indicate position of forward and reverse MSP
primers for methylated (MSPMF/MSPMR) and for unmethylated (MSPUF/
MSPUR) alleles. Simple arrows indicate bisulfite genomic sequencing
primers specific for both unmethylated and methylated sequences. The
putative transcription start site, translation start site (+1), and the end of
exon 1β (*) are indicated.
Additional file 2: Table S1. Primer sequences for methylation-specific
PCR, bisulfite genomic sequencing, and PCR amplification of exon 1β and
exon 2 of the p14ARF gene.
Additional file 3: Figure S2. Bisulfite DNA sequencing chromatograms
representing the three different methylation profiles for single CpG
dinucleotide sites. (A) DNA sequences from tumor samples showing an
overlap of both thymidine and cytosine peaks indicating a partial
methylation on CpG site located at position −31 relative to the
translation start site (top) compared with another sample showing an
unmethylated profile at the same CpG site (bottom), (B) DNA sequences
from tumor samples showing full methylation on CpG sites located at
+31 and +42 relative to the translation start site (top) compared with
another sample showing an unmethylated profile at the same CpG sites
(bottom).
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